
InfuSystem: Regulatory Backed Market Catalyst
InfuSystem: Regulatory Backed Market Catalyst
Loading news...

InfuSystem: Regulatory Backed Market Catalyst

InfuSystem (NYSE: INFU - Get Free Report) and SANUWAVE Health (OTCMKTS:SNWV - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends. Analyst Ratings This is a breakdown of recent

AWM Investment Company Inc. decreased its holdings in shares of InfuSystem Holdings, Inc. (NYSE: INFU) by 21.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,272,296 shares of the company's stock after selling 353,984 shares during the quarter. AWM Investment

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026.

Connor Clark and Lunn Investment Management Ltd. lifted its holdings in shares of InfuSystem Holdings, Inc. (NYSE: INFU) by 38.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,772 shares of the company's stock after purchasing an additional 19,554

InfuSystem Holdings offers strong growth potential and appears attractively valued after reporting positive Q3 2025 earnings results. INFU's Patient Services segment, especially oncology and wound care, is driving revenue growth, while Device Solutions faced a temporary decline. Margin improvements, new contracts, and the Apollo acquisition are enhancing profitability and expanding INFU's market share and efficiency.

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025.

InfuSystem (INFU) is prioritizing profitability and margin expansion under new CEO Carrie Lachance, shifting focus from unprofitable revenue streams. INFU's integration of Apollo Medical's billing system and new ERP is expected to drive significant operational efficiencies and margin gains in FY2026. Capital discipline enables INFU to repurchase shares and reduce debt, while growth opportunities in Wound Care and Oncology remain robust.

The consensus price target hints at a 40% upside potential for InfuSystems Holdings (INFU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

InfuSystem Holdings, Inc. ( INFU ) Q3 2025 Earnings Call November 4, 2025 9:00 AM EST Company Participants Carrie Lachance - President, CEO & Director Barry Steele - Executive VP & CFO Conference Call Participants Joe Dorame - Lytham Partners, LLC Kyle Bauser - ROTH Capital Partners, LLC, Research Division Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division James Sidoti - Sidoti & Company, LLC Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good day, and welcome to the InfuSystem Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.08 per share a year ago.

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports Third Quarter 2025 Financial Results.

InfuSystem eyes third-quarter 2025 gains as rental contracts and ERP upgrades boost margins across Patient Services and Device Solutions.

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Third Quarter 2025 Financial Results on November 4, 2025.

Inflation is expected to remain sticky and GDP expected to range between 1.7 to 2.1% in 2026. The U.S. may avoid stagflation, but mild forms are present and may linger. While investors won't likely need to pull out the 1970s-1980s investment playbook, they are wise to consider the best stocks for mild stagflation. Classic stagflation investments include precious metals, consumer staples with pricing power, defensive healthcare, multi-line insurers, and some utilities.

If you are looking for stocks that are well positioned to maintain their recent uptrend, InfuSystems Holdings (INFU) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Present at 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025.